Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 718.36 USD -0.61% Market Closed
Market Cap: 75.5B USD
Section:
 

Relative Value

The Relative Value of one REGN stock under the Base Case scenario is hidden USD. Compared to the current market price of 718.36 USD, Regeneron Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REGN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

5.3
P/S
P/S
Price to Sales
5.3
vs History
61
vs Industry
60
Median 3Y
6.5
Median 5Y
5.8
Industry
7.9
Forward
5.2
More Details
16.5
P/E
P/E
Price to Earnings
16.5
vs History
47
vs Industry
9
Median 3Y
19.2
Median 5Y
15.5
Industry
24
Forward
16.4
More Details
14.9
P/OCF
P/OCF
Price to OCF
14.9
vs History
65
vs Industry
11
Median 3Y
17
Median 5Y
17
Industry
21.6
More Details
19.5
P/FCFE
P/FCFE
Price to FCFE
19.5
vs History
60
vs Industry
9
Median 3Y
24.8
Median 5Y
21.1
Industry
23.7
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
85
vs Industry
36
Median 3Y
3.5
Median 5Y
3.7
Industry
3.4
More Details
4.9
EV/S
EV/S
Enterprise Value to Sales
4.9
vs History
61
vs Industry
59
Median 3Y
6
Median 5Y
5.7
Industry
8.3
Forward
4.8
More Details
5.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.7
vs History
60
vs Industry
60
Median 3Y
6.8
Median 5Y
6.5
Industry
10.3
More Details
15.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.7
vs History
30
vs Industry
11
Median 3Y
15.6
Median 5Y
14
Industry
6.7
Forward
13.7
More Details
17.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17.8
vs History
23
vs Industry
10
Median 3Y
17
Median 5Y
15
Industry
7.2
Forward
14.6
More Details
13.8
EV/OCF
EV/OCF
Enterprise Value to OCF
13.8
vs History
65
vs Industry
13
Median 3Y
15.8
Median 5Y
15.7
Industry
8.2
More Details
18
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18
vs History
66
vs Industry
9
Median 3Y
22.8
Median 5Y
21.8
Industry
6.7
More Details
2.3
EV/IC
EV/IC
Enterprise Value to IC
2.3
vs History
85
vs Industry
26
Median 3Y
3.6
Median 5Y
3.6
Industry
5.7
More Details

Multiples Across Competitors

REGN Competitors Multiples
Regeneron Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.6B USD 5.3 16.5 15.7 17.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 071 784.8 -161 938.1 -196 644.6 -194 400.6
US
Abbvie Inc
NYSE:ABBV
399.6B USD 6.7 170.2 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
177.5B USD 4.9 25.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.7 -527.6 -574.5 -559.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.4B USD 18.8 1 385.9 182.8 221.7
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
47.2B EUR 15.2 35.8 62 63.7
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.8 -59.4
P/S Multiple
Revenue Growth P/S to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average P/S: 3 097 631.1
5.3
6%
0.9
FR
Pharnext SCA
OTC:PNEXF
34 071 784.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.7
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.8
46%
0.4
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.2
49%
0.3
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average P/E: 212.9
16.5
9%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 938.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 385.9
N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.8
40%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBITDA: 43
15.7
11%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 644.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.8
N/A N/A
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
62
807%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBIT: 49.7
17.8
13%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 400.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
221.7
N/A N/A
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.7
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall Street Estimates
REGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.